SCHEMBL187216

SCHEMBL187216

C1=CC2C=CC1C2.C1=CC2C=CC1C2.[Rh]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1448184 1.00
SCHEMBL5611588 0.95
SCHEMBL1450030 0.90
SCHEMBL8926692 0.90
SCHEMBL2935755 0.90
Bromide SCHEMBL10937344 0.86
Hydrochloric Acid SCHEMBL913311 0.86
Hydrochloric Acid SCHEMBL3276518 0.86
Hydrochloric Acid SCHEMBL6833369 0.86
Hydrochloric Acid SCHEMBL4494190 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113874355-A Process for the manufacture of (6AR,10AR) -7-propyl-6, 6A,7,8,9,10,10A, 11-octahydro- [1,3] dioxacyclopenta [4',5':5, 6] benzo [1,2-G ] quinoline and (4AR,10AR) -1-propyl-1, 2,3,4,4A,5,10, 10A-octahydro-benzo [ G ] quinoline-6, 7-diol H.隆德贝克有限公司 2021-12-31 CN claimed
EP-3411359-B1 METHODS OF PREPARING HYDROXYLAMINE DERIVATIVES USEFUL IN THE PREPARATION OF ANTI-INFECTIVE AGENTS MERCK SHARP & DOHME (US) 2021-10-13 EP claimed
US-20240199608-A1 AHR AGONISTS ELI LILLY AND COMPANY 2024-06-20 US disclosed
WO-2024107555-A1 AHR AGONISTS ELI LILLY AND COMPANY (US) 2024-05-23 WO disclosed
WO-2023210741-A1 BENZOTRIAZOLE COMPOUND 第一三共株式会社 2023-11-02 WO disclosed
WO-2023210740-A1 BENZOTHIOPHENE COMPOUND 第一三共株式会社 2023-11-02 WO disclosed
CN-113874355-A Process for the manufacture of (6AR,10AR) -7-propyl-6, 6A,7,8,9,10,10A, 11-octahydro- [1,3] dioxacyclopenta [4',5':5, 6] benzo [1,2-G ] quinoline and (4AR,10AR) -1-propyl-1, 2,3,4,4A,5,10, 10A-octahydro-benzo [ G ] quinoline-6, 7-diol H.隆德贝克有限公司 2021-12-31 CN disclosed
WO-2017040449-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL-MYERS SQUIBB COMPANY (US) 2017-03-09 WO disclosed
US-9207296-B2 Methods and apparatus for pasadena hyperpolarization HUNTINGTON MEDICAL RESEARCH INSTITUTES (US) 2015-12-08 US disclosed
US-20150022204-A1 METHODS AND APPARATUS FOR PASADENA HYPERPOLARIZATION HUNTINGTON MEDICAL RESEARCH INSTITUTES (US) 2015-01-22 US disclosed
US-8785655-B2 Ionic liquid solvents DUBLIN CITY UNIVERSITY (IE) 2014-07-22 US disclosed
US-20140112870-A1 NMR spectroscopy and MRI methods and systems NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-04-24 US disclosed
US-8513234-B2 HIV integrase inhibitors MERCK SHARP & DOHME CORP. (US) 2013-08-20 US disclosed
US-20130006099-A1 COMPOSITIONS AND METHODS FOR METABOLIC IMAGING IMAGNX, INC. 2013-01-03 US disclosed
US-20120071661-A1 Ionic Liquid Solvents DUBLIN CITY UNIVERSITY (IE) 2012-03-22 US disclosed
EP-2401258-A1 IONIC LIQUID SOLVENTS Dublin City University (IE) 2012-01-04 EP disclosed
WO-2010097412-A1 IONIC LIQUID SOLVENTS DUBLIN CITY UNIVERSITY (IE) 2010-09-02 WO disclosed
EP-2223915-A1 Ionic liquid solvents Dublin City University (IE) 2010-09-01 EP disclosed
WO-2010042392-A2 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2010-04-15 WO disclosed
US-20100087419-A1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME LLC 2010-04-08 US disclosed